# Renerval Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renerval-biotherapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Angel (Dec 31, 2022)
- Investors on record: 2

## About

Based in Shanghai, China and founded in 2021, Heluo Xintu Biopharmaceutical (Shanghai) Co., Ltd., dba Renerval Biotherapeutics, is a biotechnology company focusing on building an artificial blood preparation platform and simultaneously constructing a globally leading regenerative medicine cell product development system based on iPSC (Induced Pluripotent Stem Cell) technology. The company was founded by Dr. Wenyuan Wang, a postdoctoral fellow at the Massachusetts Institute of Technology (MIT), a researcher at the Institute of Organic Chemistry of the Chinese Academy of Sciences (CAS) and the Biological and Chemical Intersection Research Center of CAS, and a double-appointed professor at Huashan Hospital of Fudan University.

In August 2026, Renerval Biotherapeutics raised CNY 150 million in Pre-series A funding from Efung Capital, Shanghai Minhang Financial Investment Development, Shunwei Capital, and other investors.

Renerval Biotherapeutics has, relying on core technology system, covering key technologies such as iPSC cell reprogramming, precision gene editing, directed differentiation, and organoid engineering, created a product matrix includes high-end blood bioproducts such as universal artificial regenerated platelets and artificial red blood cells which is applicable to essential transfusion scenarios such as thrombocytopenia from cancer chemotherapy, severe hematological diseases, major surgical procedures, trauma emergency care, and perioperative support. 

The company generates revenue by providing cell therapy solutions, including the production of clinical-grade regenerated platelet cells, and by driving the development of other novel products and pipelines in the field of cellular therapeutics.

The Pre-series A funding from Efung Capital and other investors in August 2026 is expected to inject a strong momentum into the company's clinical translation, industrialization construction, and technology platform iteration. In the future, the company will fully integrate industry resources, domestic and international clinical application channels, and a global business ecosystem to comprehensively empower its pipeline for rapid iteration and industrialization.

## Funding rounds

- Angel, Dec 31, 2022 — Furong Capital
- Angel, Apr 25, 2022 — Kaitai Capital

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Angel
- Furong Capital (https://capitalatlas.ai/funds/furong-capital) — Angel